Sofinnova Partners Closes €82 Mn MD Start IV Fund to Build MedTech Companies

The firm said the fund received more investor interest than expected. It will continue a strategy that Sofinnova Partners started in 2008 and has already helped create around a dozen companies.

“Sofinnova MD Start is one of the few strategies in Europe focused on creating medtech companies from the ground up. What makes the model distinctive is the active role our team plays in building and supporting every company from day one. This latest fund will allow us to scale that approach and remain a key part of Sofinnova’s platform across the life sciences value chain,” said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners.

Anne Osdoit, Partner at Sofinnova Partners, said, “We are grateful for the continued support of our existing and new limited partners. Their commitment reflects confidence in our active, hands-on approach to company building. With Sofinnova MD Start IV, we look forward to continuing to work closely with engineers, clinicians, and scientists to advance their transformative medical technologies from the lab to the clinic.”

Founded in 1972, Sofinnova Partners is a European venture capital firm that invests in healthcare and sustainability companies. The firm has offices in Paris, London, and Milan.

Sofinnova Partners operates seven investment strategies, with each one managed by a team of specialists. These strategies focus on startups and companies at different stages of growth.

Its funds include Capital, which focuses on early-stage biopharma and MedTech; MD Start, which helps create MedTech companies; and Crossover, which invests in growing BioTech and MedTech businesses. Other strategies include Industrial Biotech for sustainable startups, Telethon for early-stage Italian science, Digital Medicine for TechBio and HealthTech, and Biovelocita, a BioTech accelerator developed with research organisations.

Read Also- Reactive Technologies Gets €19 Mn EIB Funding for Grid Stability Technology